1. Mosaic RBD nanoparticles induce intergenus cross-reactive antibodies and protect against SARS-CoV-2 challenge
- Author
-
Dan Bi Lee, Hyojin Kim, Ju Hwan Jeong, Ui Soon Jang, Yuyeon Jang, Seokbeom Roh, Hyunbum Jeon, Eun Jeong Kim, Su Yeon Han, Jin Young Maeng, Stefan Magez, Magdalena Radwanska, Ji Young Mun, Hyun Sik Jun, Gyudo Lee, Min-Suk Song, Hye-Ra Lee, Mi Sook Chung, Yun Hee Baek, Kyung Hyun Kim, Department of Bio-engineering Sciences, and Cellular and Molecular Immunology
- Subjects
Spike Glycoprotein, Coronavirus/genetics ,mice ,Multidisciplinary ,SARS-CoV-2 ,COVID-19/prevention & control ,Medicine and Health Sciences ,Humans ,Animals ,Biology and Life Sciences ,nanoparticles ,Antibodies, Viral ,Antibodies, Neutralizing - Abstract
Recurrent spillovers of α- and β-coronaviruses (CoV) such as severe acute respiratory syndrome (SARS)-CoV, Middle East respiratory syndrome-CoV, SARS-CoV-2, and possibly human CoV have caused serious morbidity and mortality worldwide. In this study, six receptor-binding domains (RBDs) derived from α- and β-CoV that are considered to have originated from animals and cross-infected humans were linked to a heterotrimeric scaffold, proliferating cell nuclear antigen (PCNA) subunits, PCNA1, PCNA2, and PCNA3. They assemble to create a stable mosaic multivalent nanoparticle, 6RBD-np, displaying a ring-shaped disk with six protruding antigens, like jewels in a crown. Prime-boost immunizations with 6RBD-np in mice induced significantly high Ab titers against RBD antigens derived from α- and β-CoV and increased interferon (IFN-γ) production, with full protection against the SARS-CoV-2 wild type and Delta challenges. The mosaic 6RBD-np has the potential to induce intergenus cross-reactivity and to be developed as a pan-CoV vaccine against future CoV spillovers.
- Published
- 2023